Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 2

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 2
---
This prospectus also relates to the offer and sale from time to time by the selling stockholders named herein (the “Selling Stockholders”) of up to an aggregate of 1,703,946 shares of Common Stock (the “Resale Shares”), consisting of (i) up to 275,000 shares of Common Stock (the “September 2025 Warrant Shares”) issuable upon the exercise of warrants to purchase up to an aggregate of 275,000 shares of Common Stock that were issued on September 30, 2025 (the “September 2025 Warrants”) and (ii) up to 1,428,946 shares of Common Stock (the “November 2025 Warrant Shares”) issuable upon the exercise of (A) a warrant to purchase up to an aggregate of 1,356,594 shares of Common Stock (the “November 2025 Investor Warrant”) and (B) placement agent warrants to purchase up to an aggregate of 72,352 shares of Common Stock (the “November 2025 Placement Agent Warrants” and together with the November 2025 Investor Warrant, the “November 2025 Warrants”) that were each issued on November 25, 2025.

We will not receive the proceeds from the resale of the Resale Shares hereunder; however, we will receive the proceeds from the exercise of any Exchange Warrants, September 2025 Warrants, and November 2025 Warrants.

The Exchange Warrants were issued on July 28, 2025, pursuant to the warrant exchange agreements (each, a “Warrant Exchange Agreement” and collectively, the “Warrant Exchange Agreements”) that we entered into on July 22, 2025 with certain holders (the “Tranche B Investors”) of the Company’s existing Tranche B warrants to purchase shares of Common Stock (the “October 2024 Noteholder Warrants”). Pursuant to the Warrant Exchange Agreements, the Company and the Tranche B Investors, in reliance on Section 3(a)(9) of the Securities Act, effected a voluntary securities exchange whereby the Tranche B Investors exchanged their October 2024 Noteholder Warrants, which were then exercisable for an aggregate of 107,142 shares of Common Stock at an exercise price of $36.40 per share, originally issued pursuant to that certain Securities Purchase Agreement, dated October 7, 2024, by and among the Company and the investors named therein, for the